Literature DB >> 3010835

Inhibition of murine cytomegalovirus lung infection and interstitial pneumonitis by acyclovir and 9-(1,3-dihydroxy-2-propoxymethyl)guanine.

J D Shanley, J Morningstar, M C Jordan.   

Abstract

We compared the effects of acyclovir (ACV) and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) on murine cytomegalovirus (MCMV) replication in lung and salivary gland tissues, the evolution of interstitial pneumonitis in vivo, and MCMV replication in mouse embryo cells in vitro. As measured by plaque reduction, ACV was more active than DHPG in vitro. In vivo, whether administered orally by gastric intubation or in the drinking water, or subcutaneously, DHPG was more effective than ACV in reducing MCMV titers in lung or salivary gland tissues. This was true in both normal and cyclophosphamide-treated mice. Neither drug was able to prevent MCMV interstitial pneumonitis, despite substantial reductions in virus titer, but both drugs reduced the severity of the pneumonitis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3010835      PMCID: PMC180213          DOI: 10.1128/AAC.28.2.172

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Pathogenesis of reactivated latent murine cytomegalovirus infection.

Authors:  J D Shanley; M C Jordan; M L Cook; J G Stevens
Journal:  Am J Pathol       Date:  1979-04       Impact factor: 4.307

2.  The relation of viral replication to interstitial pneumonitis in murine cytomegalovirus lung infection.

Authors:  J D Shanley; E L Pesanti
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

Review 3.  Overview of acyclovir pharmacokinetic disposition in adults and children.

Authors:  M R Blum; S H Liao; P de Miranda
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

4.  The pathogenesis of pneumonitis due to murine cytomegalovirus.

Authors:  J D Shanley; E L Pesanti; K M Nugent
Journal:  J Infect Dis       Date:  1982-09       Impact factor: 5.226

5.  Treatment of cytomegalovirus pneumonia with high-dose acyclovir.

Authors:  J C Wade; M Hintz; R McGuffin; S C Springmeyer; J D Connor; J D Meyers
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

6.  Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation.

Authors:  J D Meyers; R W McGuffin; P E Neiman; J W Singer; E D Thomas
Journal:  J Infect Dis       Date:  1980-05       Impact factor: 5.226

7.  Thymidine kinase not required for antiviral activity of acyclovir against mouse cytomegalovirus.

Authors:  W H Burns; J R Wingard; W J Bender; R Saral
Journal:  J Virol       Date:  1981-09       Impact factor: 5.103

8.  Treatment of cytomegaloviral pneumonia with high-dose acyclovir and human leukocyte interferon.

Authors:  J C Wade; R W McGuffin; S C Springmeyer; B Newton; J W Singer; J D Meyers
Journal:  J Infect Dis       Date:  1983-09       Impact factor: 5.226

9.  Role of macrophages in resistance to murine cytomegalovirus.

Authors:  M K Selgrade; J E Osborn
Journal:  Infect Immun       Date:  1974-12       Impact factor: 3.441

10.  Efficacy of acyclovir against mouse cytomegalovirus in vivo.

Authors:  J R Wingard; W J Bender; R Saral; W H Burns
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

View more
  12 in total

1.  9-(1-3-Dihydroxy-2-propoxymethyl)guanine prevents death but not immunity in murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice.

Authors:  E J Wilson; D N Medearis; L A Hansen; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

2.  Sequence and transcriptional analysis of the guinea pig cytomegalovirus UL97 homolog.

Authors:  D S Fox; M R Schleiss
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

3.  Ganciclovir transiently attenuates murine cytomegalovirus-associated renal allograft inflammation.

Authors:  Masako Shimamura; Ute Saunders; Brian Rha; Lingling Guo; Kevin A Cassady; James F George; William J Britt
Journal:  Transplantation       Date:  2011-10-15       Impact factor: 4.939

4.  Ganciclovir prophylaxis for cochlear pathophysiology during experimental guinea pig cytomegalovirus labyrinthitis.

Authors:  N K Woolf; J W Ochi; E J Silva; P A Sharp; J P Harris; D D Richman
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

Review 5.  Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections.

Authors:  D Faulds; R C Heel
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

6.  Analysis of the complete DNA sequence of murine cytomegalovirus.

Authors:  W D Rawlinson; H E Farrell; B G Barrell
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

7.  Effect of 2'-nor-cyclic GMP against guinea pig cytomegalovirus infection.

Authors:  Z H Yang; H L Lucia; R L Tolman; R J Colonno; G D Hsiung
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

8.  Complete sequence and genomic analysis of rhesus cytomegalovirus.

Authors:  Scott G Hansen; Lisa I Strelow; David C Franchi; David G Anders; Scott W Wong
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  Human cytomegalovirus in a SCID-hu mouse: thymic epithelial cells are prominent targets of viral replication.

Authors:  E S Mocarski; M Bonyhadi; S Salimi; J M McCune; H Kaneshima
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

10.  Suppression of herpes simplex virus type 1 (HSV-1)-induced pneumonia in mice by inhibition of inducible nitric oxide synthase (iNOS, NOS2).

Authors:  H Adler; J L Beland; N C Del-Pan; L Kobzik; J P Brewer; T R Martin; I J Rimm
Journal:  J Exp Med       Date:  1997-05-05       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.